Daniel B Rifkin

List of Publications by Year
in descending order

85	16,619	43973 48	54797 84
papers	citations	h-index	g-index

86	86	86	15506
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The role of <scp>LTBPs</scp> in <scp>TGF</scp> beta signaling. Developmental Dynamics, 2022, 251, 75-84.	0.8	20
2	Fibrillin-1 deficiency in the outer perichondrium causes longitudinal bone overgrowth in mice with Marfan syndrome. Human Molecular Genetics, 2022, 31, 3281-3289.	1.4	2
3	Osteoblastic monocyte chemoattractant protein-1 (MCP-1) mediation of parathyroid hormone's anabolic actions in bone implicates TGF-Î² signaling. Bone, 2021, 143, 115762.	1.4	9
4	Intraarticular injection of liposomal adenosine reduces cartilage damage in established murine and rat models of osteoarthritis. Scientific Reports, 2020, 10, 13477.	1.6	18
5	LTBPs in biology and medicine: LTBP diseases. Matrix Biology, 2018, 71-72, 90-99.	1.5	72
6	LTBP3 Pathogenic Variants Predispose Individuals to Thoracic Aortic Aneurysms and Dissections. American Journal of Human Genetics, 2018, 102, 706-712.	2.6	51
7	Enamel and dental anomalies in latentâ€transforming growth factor betaâ€binding protein 3 mutant mice. European Journal of Oral Sciences, 2017, 125, 8-17.	0.7	13
8	Latent TGF-Î² binding protein-1 deficiency decreases female fertility. Biochemical and Biophysical Research Communications, 2017, 482, 1387-1392.	1.0	9
9	Pulsed Electromagnetic Field Regulates MicroRNA 21 Expression to Activate TGF-Î² Signaling in Human Bone Marrow Stromal Cells to Enhance Osteoblast Differentiation. Stem Cells International, 2017, 2017, 1-17.	1.2	48
10	Regulation of the Bioavailability of TGF-Î² and TGF-Î²-Related Proteins. Cold Spring Harbor Perspectives in Biology, 2016, 8, a021907.	2.3	305
11	L59 TGF-Î² LAP degradation products serve as a promising blood biomarker for liver fibrogenesis in mice. Fibrogenesis and Tissue Repair, 2015, 8, 17.	3.4	10
12	Isolation and cytokine analysis of lamina propria lymphocytes from mucosal biopsies of the human colon. Journal of Immunological Methods, 2015, 421, 27-35.	0.6	18
13	Latent TGF-Î²-binding proteins. Matrix Biology, 2015, 47, 44-53.	1.5	346
14	Mutations in the latent TGF-beta binding protein 3 (LTBP3) gene cause brachyolmia with amelogenesis imperfecta. Human Molecular Genetics, 2015, 24, 3038-3049.	1.4	40
15	Abrogation of both short and long forms of latent transforming growth factor-Î² binding protein-1 causes defective cardiovascular development and is perinatally lethal. Matrix Biology, 2015, 43, 61-70.	1.5	23
16	Function of Latent TGFÎ² Binding Protein 4 and Fibulin 5 in Elastogenesis and Lung Development. Journal of Cellular Physiology, 2015, 230, 226-236.	2.0	41
17	Genetic analysis of the contribution of LTBP-3 to thoracic aneurysm in Marfan syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14012-14017.	3.3	47
18	Noninvasive diagnosis and management of spontaneous intracranial hypotension in patients with marfan syndrome: Case Report and Review of the Literature. , 2014, 5, 8.		17

#	Article	IF	Citations
19	Genetic Suppression of Inflammation Blocks the Tumor-Promoting Effects of TGF-Î² in Gastric Tissue. Cancer Research, 2014, 74, 2642-2651.	0.4	13
20	LAP degradation product reflects plasma kallikrein-dependent TGF-Î² activation in patients with hepatic fibrosis. SpringerPlus, 2014, 3, 221.	1.2	23
21	Unchaining the beast; insights from structural and evolutionary studies on TGFÎ² secretion, sequestration, and activation. Cytokine and Growth Factor Reviews, 2013, 24, 355-372.	3.2	99
22	Production of Gastrointestinal Tumors in Mice by Modulating Latent TGF-Î²1 Activation. Cancer Research, 2013, 73, 459-468.	0.4	17
23	Latent TGF-Î² binding protein 4 promotes elastic fiber assembly by interacting with fibulin-5. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 2852-2857.	3.3	122
24	Matrix control of transforming growth factor-Â function. Journal of Biochemistry, 2012, 152, 321-329.	0.9	224
25	Specificity of latent TGFâ€Î² binding protein (LTBP) incorporation into matrix: Role of fibrillins and fibronectin. Journal of Cellular Physiology, 2012, 227, 3828-3836.	2.0	159
26	LTBPs, more than just an escort service. Journal of Cellular Biochemistry, 2012, 113, 410-418.	1.2	117
27	Control of lung development by latent TGFâ€Î² binding proteins. Journal of Cellular Physiology, 2011, 226, 1499-1509.	2.0	27
28	Long form of latent TGFâ€Î² binding protein 1 (Ltbp1L) regulates cardiac valve development. Developmental Dynamics, 2011, 240, 176-187.	0.8	47
29	Bone matrix to growth factors: location, location, location. Journal of Cell Biology, 2010, 190, 949-951.	2.3	5
30	E-selectin ligandâ€“1 regulates growth plate homeostasis in mice by inhibiting the intracellular processing and secretion of mature TGF-Î². Journal of Clinical Investigation, 2010, 120, 2474-2485.	3.9	24
31	Latent Transforming Growth Factor Î²-binding Proteins and Fibulins Compete for Fibrillin-1 and Exhibit Exquisite Specificities in Binding Sites. Journal of Biological Chemistry, 2009, 284, 16872-16881.	1.6	146
32	Fâ€spondin, a neuroregulatory protein, is upâ€regulated in osteoarthritis and regulates cartilage metabolism via TGFâ€Î² activation. FASEB Journal, 2009, 23, 79-89.	0.2	56
33	Extracellular microfibrils: contextual platforms for TGFÎ² and BMP signaling. Current Opinion in Cell Biology, 2009, 21, 616-622.	2.6	196
34	Dual functions for LTBP in lung development: LTBPâ€4 independently modulates elastogenesis and TGFâ€Î² activity. Journal of Cellular Physiology, 2009, 219, 14-22.	2.0	62
35	Mutations in LTBP4 Cause a Syndrome of Impaired Pulmonary, Gastrointestinal, Genitourinary, Musculoskeletal, and Dermal Development. American Journal of Human Genetics, 2009, 85, 593-605.	2.6	131
36	Perturbation of transforming growth factor (TGF)-ÃŸ1 association with latent TGF-Î² binding protein yields inflammation and tumors. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 18758-18763.	3.3	95

#	Article	IF	Citations
37	In vitro and in vivo evidence for shear-induced activation of latent transforming growth factor-Î²1. Blood, 2008, 112, 3650-3660.	0.6	126
38	Long form of latent TGF-Î² binding protein 1 (Ltbp1L) is essential for cardiac outflow tract septation and remodeling. Development (Cambridge), 2007, 134, 3723-3732.	1.2	81
39	Myofibroblast contraction activates latent TGF-Î²1 from the extracellular matrix. Journal of Cell Biology, 2007, 179, 1311-1323.	2.3	1,118
40	Isoform-Specific Activation of Latent Transforming Growth Factor Î² (LTGF-Î²) by Reactive Oxygen Species. Radiation Research, 2006, 166, 839-848.	0.7	246
41	Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome. Science, 2006, 312, 117-121.	6.0	1,591
42	A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nature Genetics, 2005, 37, 275-281.	9.4	1,543
43	Latent Transforming Growth Factor-Î² (TGF-Î²) Binding Proteins: Orchestrators of TGF-Î² Availability. Journal of Biological Chemistry, 2005, 280, 7409-7412.	1.6	371
44	Fibronectin is required for integrin o:vÎ²6â€mediated activation of latent TGFâ€Î² complexes containing LTBPâ€1. FASEB Journal, 2005, 19, 1798-1808.	0.2	163
45	Expression of truncated latent TGF-Î²-binding protein modulates TGF-Î² signaling. Journal of Cell Science, 2005, 118, 2177-2187.	1.2	38
46	Amino Acid Requirements for Formation of the TGF-Î²-Latent TGF-Î² Binding Protein Complexes. Journal of Molecular Biology, 2005, 345, 175-186.	2.0	55
47	Lung Alveolar Septation Defects in Ltbp-3-Null Mice. American Journal of Pathology, 2005, 167, 419-428.	1.9	58
48	Integrin Î±VÎ²6-mediated activation of latent TGF-Î² requires the latent TGF-Î² binding protein-1. Journal of Cell Biology, 2004, 165, 723-734.	2.3	438
49	Growth retardation as well as spleen and thymus involution in latent TGF-? binding protein (Ltbp)-3 null mice. Journal of Cellular Physiology, 2003, 196, 319-325.	2.0	22
50	Solution Structure of the Third TB Domain from LTBP1 Provides Insight into Assembly of the Large Latent Complex that Sequesters Latent TGF-Î². Journal of Molecular Biology, 2003, 334, 281-291.	2.0	45
51	Molecular cloning of the mouse Ltbp-1 gene reveals tissue specific expression of alternatively spliced forms. Gene, 2003, 308, 31-41.	1.0	23
52	Cell signaling events: a view from the matrix. Matrix Biology, 2003, 22, 101-107.	1.5	149
53	Making sense of latent TGFÎ² activation. Journal of Cell Science, 2003, 116, 217-224.	1.2	1,462
54	Latent Transforming Growth Factor Î²-binding Protein 1 Interacts with Fibrillin and Is a Microfibril-associated Protein. Journal of Biological Chemistry, 2003, 278, 2750-2757.	1.6	495

#	Article	IF	Citations
55	Bone abnormalities in latent TGF-Î² binding protein (Ltbp)-3â€“null mice indicate a role for Ltbp-3 in modulating TGF-Î² bioavailability. Journal of Cell Biology, 2002, 156, 227-232.	2.3	200
56	The integrin Î±VÎ²6binds and activates latent TGFÎ²3. FEBS Letters, 2002, 511, 65-68.	1.3	146
57	Latent TGF-Î² binding protein-3 (LTBP-3) requires binding to TGF-Î² for secretion. FEBS Letters, 2002, 517, 277-280.	1.3	44
58	The Latent Transforming Growth Factor-Î²â€“binding Protein-1 Promotes In Vitro Differentiation of Embryonic Stem Cells into Endothelium. Molecular Biology of the Cell, 2000, 11, 4295-4308.	0.9	72
59	Proteolytic control of growth factor availability. Apmis, 1999, 107, 80-85.	0.9	145
60	A Mechanism for Regulating Pulmonary Inflammation and Fibrosis: The Integrin Î±vÎ²6 Binds and Activates Latent TGF Î²1. Cell, 1999, 96, 319-328.	13.5	1,867
61	Interactions between Growth Factors and Integrins: Latent Forms of Transforming Growth Factor-Î² Are Ligands for the Integrin Î±vÎ²1. Molecular Biology of the Cell, 1998, 9, 2627-2638.	0.9	231
62	Latent Transforming Growth Factor-Î² Binding Protein Domains Involved in Activation and Transglutaminase-dependent Cross-Linking of Latent Transforming Growth Factor-Î². Journal of Cell Biology, 1997, 136, 1151-1163.	2.3	359
63	Biological Roles of Fibroblast Growth Factor-2*. Endocrine Reviews, 1997, 18, 26-45.	8.9	748
64	TGFâ€Î² Latency: Biological Significance and Mechanisms of Activation. Stem Cells, 1997, 15, 190-197.	1.4	233
65	Characterization of Fibroblast Growth Factor-2 Binding to Ribosomes. Growth Factors, 1996, 13, 219-228.	0.5	11
66	Identification and Characterization of an Eight-cysteine Repeat of the Latent Transforming Growth Factor-Î² Binding Protein-1 that Mediates Bonding to the Latent Transforming Growth Factor-Î²1. Journal of Biological Chemistry, 1996, 271, 29891-29896.	1.6	128
67	Lipopolysaccharide inhibits activation of latent transforming growth factor-? in bovine endothelial cells. Journal of Cellular Physiology, 1995, 163, 210-219.	2.0	14
68	Tumor cells secrete an Angiogenic factor that stimulates basic fibroblast growth factor and Urokinase expression in Vascular Endothelial cells. Journal of Cellular Physiology, 1994, 161, 1-14.	2.0	37
69	Studies on FGF-2: Nuclear localization and function of high molecular weight forms and receptor binding in the absence of heparin. Molecular Reproduction and Development, 1994, 39, 102-105.	1.0	27
70	Mechanism of retinoid-induced activation of latent transforming growth factor-? in bovine endothelial cells. Journal of Cellular Physiology, 1993, 155, 323-332.	2.0	109
71	Mechanism of action of angiostatic steroids: Suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. Journal of Cellular Physiology, 1993, 155, 568-578.	2.0	139
72	TGF-Î²: Structure, Function, and Formation. Thrombosis and Haemostasis, 1993, 70, 177-179.	1.8	50

#	Article	IF	Citations
73	A Wound Healing Model Using Healingâ€impaired Diabetic Mice. Journal of Dermatology, 1992, 19, 673-675.	0.6	61
74	Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity. Journal of Cellular Physiology, 1992, 150, 258-263.	2.0	181
75	Basic fibroblast growth factor, a protein devoid of secretory signal sequence, is released by cells via a pathway independent of the endoplasmic reticulum-Golgi complex. Journal of Cellular Physiology, 1992, 151, 81-93.	2.0	421
76	Cell density dependent effects of TGF-? demonstrated by a plasminogen activator-based assay for TGF-?. Journal of Cellular Physiology, 1992, 152, 48-55.	2.0	25
77	Extracellular matrix regulation of growth factor and protease activity. Current Opinion in Cell Biology, 1991, 3, 817-823.	2.6	119
78	Release of basic fibroblast growth factor, an angiogenic factor devoid of secretory signal sequence: A trivial phenomenon or a novel secretion mechanism?. Journal of Cellular Biochemistry, 1991, 47, 201-207.	1.2	131
79	Bimodal relationship between invasion of the amniotic membrane and plasminogen activator activity. International Journal of Cancer, 1990, 46, 56-60.	2.3	45
80	Long-Term Culture of Human Bone Marrow Stromal Cells in the Presence of Basic Fibroblast Growth Factor. Growth Factors, 1990, 3, 231-236.	0.5	80
81	Both normal and tumor cells produce basic fibroblast growth factor. Journal of Cellular Physiology, 1986, 129, 273-276.	2.0	234
82	Stimulation of motility in cultured bovine capillary endothelial cells by angiogenic preparations. Journal of Cellular Physiology, 1984, 119, 247-254.	2.0	22
83	Isolation of the major serine protease inhibitor from the 5-day serum-free conditioned medium of human embryonic lung cells and demonstration that it is fetuin. Journal of Cellular Physiology, 1981, 109, 1-15.	2.0	39
84	Studies on the control of plasminogen activator production by cultured human embryonic lung cells: Requirements for inhibition by corticosteroids. Journal of Cellular Physiology, 1980, 105, 417-422.	2.0	12
85	Tumorigenicity of revertants from an SV40-transformed line. Journal of Supramolecular Structure, 1979, 11, 539-546.	2.3	13